

Clinical Features of Hypercortisolism



A spectrum of signs and symptoms

Clinical Features Associated With Hypercortisolism and Their Prevalence¹



Round face	81%-90%
*Plethora	70%-90%
Hirsutism	56%-75%
Hair loss	31%
Prominent neck fat pad	50%



Recent weight gain	70%-95%
Overweight	21%-48%
Obesity	32%-41%
*Easy bruising	35%-65%
*Purple striae	<50%
Thin skin	37%



*Proximal muscle weakness, myopathy 60%-82%

*Discriminatory features for hypercortisolism; most have low sensitivity.²

1. Braun LT, et al. *Front Endocrinol (Lausanne)*. 2019;10:766. 2. Nieman LK, et al. *J Clin Endocrinol Metab*. 2008;93:1526-1540.

Clinical suspicion is based on a spectrum of clinical features

Accumulation of features should raise clinical suspicion and prompt a biochemical workup

Circulatory¹

- Hypertension
- Hypokalemia
- Peripheral edema

Endocrine¹

- Type 2 diabetes
- Incidental adrenal mass

Skeletal¹

- Vertebral osteoporosis

Dermatologic¹

- Poor skin healing
- Thin skin

Neuro/Psychiatric¹⁻⁶

- Depression
- Decreased concentration
- Impaired memory
- Insomnia
- Irritability
- Mood changes
- Delusions
- Headache

Gynecologic¹

- Menstrual abnormalities
- Polycystic ovary syndrome
- Hirsutism or female balding
- Decreased libido

Immune¹

- Unusual infections

Skin¹

- Easy bruising
- Facial plethora
- Reddish, purple striae

Muscle¹

- Proximal myopathy

Renal¹

- Kidney stones

Metabolic^{1,6}


- Obesity
- Prominent neck fat pad
- Facial fullness
- Supraclavicular fullness
- Weight gain
- Increased appetite

New signs, symptoms, and clinical presentations associated with CS diagnosis continue to be recognized

CS=Cushing's syndrome.

1. Nieman LK, et al. *J Clin Endocrinol Metab.* 2008;93(5):1526-1540. 2. Martins JM, et al. *J Endocrinol Metab.* 2022;12(1):40-48. 3. Dugandzic MK, et al. *Metabolites.* 2022;12(11):1033. doi:10.3390/metabo12111033 4. Gonzalez A, et al. *World Neurosurg.* 2019;126:331-335. 5. Telbizova T, et al. *J of IMAB.* 2020;26:3443-3448. 6. Alfakhri AS 4th, et al. *Cureus.* 2022;14(6):e25761. doi:10.7759/cureus.25761

Wide spectrum of comorbidities associated with hypercortisolism




1. Ilias I, et al. *J Clin Endocrinol Metab.* 2005;90:4955-4962. 2. Ejas S, et al. *Cancer.* 2011;117:4381-4389. 3. Broder MS, et al. *Pituitary.* 2015;18:796-802. 4. Braun LT, et al. *Front Endocrinol (Lausanne).* 2019;10:766. doi:10.3389/fendo.2019.00766 5. Huan C, et al. *Biomed Mater Eng.* 2014;24(6):3439-3446. 6. De Alcubierre D, et al. *J Endocrinol Invest.* 2023;46(10):1961-1982. 7. Wagner J, et al. *Front Endocrinol (Lausanne).* 2019;9:805. doi:10.3389/fendo.2018.00805 8. Suarez MG, et al. *J Endocr Soc.* 2019;4(2):bvz033. doi:10.1210/jeendo/bvz033

Hypercortisolism exists as a continuum

Biochemical severity

- **Presence of hypercortisolism**
 - 24-h UFC
 - DST
 - LNSC
- **ACTH-independence**
 - Baseline ACTH
 - Sex-adjusted DHEA-S levels



Clinical severity

- **Metabolic abnormalities**
 - Hypertension
 - T2DM
 - Decreased bone density
 - VTE
- **Physical findings**
 - Central obesity
 - Supraclavicular and/or dorsocervical fat pads
 - Rounding of face
 - Skin changes
 - Proximal muscle weakness


ACTH=adrenocorticotropic hormone; DHEA-S=dehydroepiandrosterone sulfate; DST=dexamethasone suppression test; LNSC=late-night salivary cortisol; MACS=mild autonomous cortisol secretion; T2DM=type 2 diabetes mellitus; UFC=urinary free cortisol; VTE=venous thromboembolism.

Li D, et al. *Eur J Endocrinol.* 2023;188(7):603-612.

Cortisol activity is influenced by cortisol levels and GR sensitivity

Cortisol levels^{1,2}


- Cortisol synthesis
- Serum cortisol levels
 - CBG affinity and concentrations
- 11 β -HSD 1/2 regulation



Cortisol

GR sensitivity^{1,2}


- GR mutations
- GR isoforms/variants
- GR post-translational modifications



GR

Spectrum of clinical severity

Cortisol levels and GR sensitivity drive clinical severity in hypercortisolism^{1,2}



GC=glucocorticoid.

1. Timmermans S, et al. *Front Immunol.* 2019;10:1545. doi:10.3389/fimmu.2019.01545 2. Vandevyver S, et al. *Endocr Rev.* 2014;35:671-693.